Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
Lucas V.A. Boersma,Hueseyin Ince,Stephan Kische,Evgeny Pokushalov,Thomas Schmitz,Boris Schmidt,Tommaso Gori,Felix Meincke,Alexey Vladimir Protopopov,Timothy R. Betts,David P. Foley,Horst Sievert,Patrizio Mazzone,Tom De Potter,Elisa Vireca,Kenneth M. Stein,Martin Bergmann +16 more
Reads0
Chats0
TLDR
This method of stroke risk reduction appears to be safe and effective with an ischemic stroke rate as low as 1.1%, even though 73% of patients had a contraindication to and were not using oral anticoagulation.About:
This article is published in Heart Rhythm.The article was published on 2017-09-01 and is currently open access. It has received 301 citations till now. The article focuses on the topics: Stroke & Atrial fibrillation.read more
Citations
More filters
Journal ArticleDOI
Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry
TL;DR: The Watchman FLX is a device upgrade of the Watchman 2.5 that incorporates several design enhancements intended to simplify left atrial appendage occlusion (LAAO) and improve procedural outcomes as mentioned in this paper .
Journal ArticleDOI
Effectiveness and safety of transcatheter left atrial appendage closure
TL;DR: The WATCHMAN LAA Closure device as mentioned in this paper is the only FDA-approved device in the USA and Japan that is indicated in high bleeding risk and high stroke risk non-valvular atrial fibrillation patients.
Journal ArticleDOI
Left Atrial Appendage Occlusion in the Management of Stroke in Patients With Atrial Fibrillation
Amole Ojo,Srikanth Yandrapalli,Granit Veseli,Mohammad Karim,Wilbert S. Aronow,Mala Sharma,William H. Frishman,Srihari S. Naidu,Jason T. Jacobson,Sei Iwai +9 more
TL;DR: Left atrial appendage occlusion (LAAO) devices, and those being developed, have shown promise in reducing bleeding risk in AF patients due to the reduced overall need for anticoagulation, while maintaining efficacy in preventing thromboembolism.
Journal ArticleDOI
Percutaneous Left Atrial Appendage Closure: Review of Anatomy, Imaging, and Outcomes
Issa Pour-Ghaz,Mark Heckle,Miguel A. Maturana,Michael P. Seitz,Pegah Zare,Rami N. Khouzam,Rajesh Kabra +6 more
TL;DR: It can be demonstrated that the WATCHMAN device is an efficacious device for stroke prevention in patients who are not candidates for anticoagulation, and the recently approved Amulet device has shown comparable outcomes.
Journal ArticleDOI
Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance
Marc Llagostera-Martín,Hector Cubero-Gallego,Aleksandra Mas-Stachurska,Neus Salvatella,Andrea Sánchez-Carpintero,Helena Tizón-Marcos,Marcos García-Guimaraes,Alicia Calvo-Fernández,Luis Molina,Beatriz Vaquerizo +9 more
TL;DR: The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC) and first registries showed a high rate of device implantation success.
References
More filters
Journal ArticleDOI
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof,Stefano Benussi,Dipak Kotecha,Anders Ahlsson,Dan Atar,Barbara Casadei,Manuel Castellá,Hans-Christoph Diener,Hein Heidbuchel,Jeroen M.L. Hendriks,Gerhard Hindricks,Antonis S. Manolis,Jonas Oldgren,Bogdan A. Popescu,Ulrich Schotten,Bart P. Van Putte,Panagiotis Vardas,Stefan Agewall,John Camm,Gonzalo Barón Esquivias,Werner Budts,Scipione Carerj,Filip Casselman,Antonio Coca,Raffaele De Caterina,Spiridon Deftereos,Dobromir Dobrev,José M. Ferro,Gerasimos Filippatos,Donna Fitzsimons,Bulent Gorenek,Maxine Guenoun,Stefan H. Hohnloser,Philippe Kolh,Gregory Y.H. Lip,Athanasios J. Manolis,John J.V. McMurray,Piotr Ponikowski,Raphael Rosenhek,Frank Ruschitzka,Irina Savelieva,Sanjay Sharma,Piotr Suwalski,Juan Tamargo,Clare J Taylor,Isabelle C. Van Gelder,Adriaan A. Voors,Stephan Windecker,José Luis Zamorano,Katja Zeppenfeld +49 more
TL;DR: The Task Force for the management of atrial fibrillation of the European Society of Cardiology has been endorsed by the European Stroke Organisation (ESO).
Journal ArticleDOI
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)
Journal ArticleDOI
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran,Sunil V. Rao,Deepak L. Bhatt,C. Michael Gibson,Adriano Caixeta,John W. Eikelboom,Sanjay Kaul,Stephen D. Wiviott,Venu Menon,Eugenia Nikolsky,Victor L. Serebruany,Marco Valgimigli,Pascal Vranckx,David P. Taggart,Joseph F. Sabik,Donald E. Cutlip,Mitchell W. Krucoff,E. Magnus Ohman,Philippe Gabriel Steg,Harvey D. White +19 more
TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
Journal ArticleDOI
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
TL;DR: Data suggest that left atrial appendage obliteration is a strategy of potential value for stroke prophylaxis in nonrheumatic atrial fibrillation.
Journal ArticleDOI
Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
David R. Holmes,Saibal Kar,Matthew J. Price,Brian Whisenant,Horst Sievert,Shephal K. Doshi,Kenneth C. Huber,Vivek Y. Reddy +7 more
TL;DR: In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke prevention or SE >7 days' post-procedure in patients with NVAF who do not have an absolute contraindication to short-termwarfarin therapy.
Related Papers (5)
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof,Stefano Benussi,Dipak Kotecha,Anders Ahlsson,Dan Atar,Barbara Casadei,Manuel Castellá,Hans-Christoph Diener,Hein Heidbuchel,Jeroen M.L. Hendriks,Gerhard Hindricks,Antonis S. Manolis,Jonas Oldgren,Bogdan A. Popescu,Ulrich Schotten,Bart P. Van Putte,Panagiotis Vardas,Stefan Agewall,John Camm,Gonzalo Barón Esquivias,Werner Budts,Scipione Carerj,Filip Casselman,Antonio Coca,Raffaele De Caterina,Spiridon Deftereos,Dobromir Dobrev,José M. Ferro,Gerasimos Filippatos,Donna Fitzsimons,Bulent Gorenek,Maxine Guenoun,Stefan H. Hohnloser,Philippe Kolh,Gregory Y.H. Lip,Athanasios J. Manolis,John J.V. McMurray,Piotr Ponikowski,Raphael Rosenhek,Frank Ruschitzka,Irina Savelieva,Sanjay Sharma,Piotr Suwalski,Juan Tamargo,Clare J Taylor,Isabelle C. Van Gelder,Adriaan A. Voors,Stephan Windecker,José Luis Zamorano,Katja Zeppenfeld +49 more